The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation

Martin J. Page¹, Douglas B. Kell¹,²,³, and Etheresia Pretorius¹

Abstract
Lipopolysaccharide (LPS) is the main structural component of the outer membrane of most Gram-negative bacteria and has diverse immunostimulatory and procoagulant effects. Even though LPS is well described for its role in the pathology of sepsis, considerable evidence demonstrates that LPS-induced signalling and immune dysregulation are also relevant in the pathophysiology of many diseases, characteristically where endotoxaemia is less severe. These diseases are typically chronic and progressive in nature and span broad classifications, including neurodegenerative, metabolic, and cardiovascular diseases. This Review reappraises the mechanisms of LPS-induced signalling and emphasises the crucial contribution of LPS to the pathology of multiple chronic diseases, beyond conventional sepsis. This perspective asserts that new ways of approaching chronic diseases by targeting LPS-driven pathways may be of therapeutic benefit in a wide range of chronic inflammatory conditions.

Keywords
lipopolysaccharide, coagulation, chronic inflammation, immunopathology, noncommunicable diseases

Received 14 November 2021; accepted 11 January 2022

Introduction
Considerable research into the impact of the microbiome on human health strongly implicates a role for microorganisms, their molecular products, and the host defences against them in the complex aetiopathogenesis of a broad range of chronic inflammatory diseases. Various bacterial components are recognised by the innate immune system. One of the most well studied of these is lipopolysaccharide (LPS; also known as endotoxin) that derives from the cell wall of Gram-negative bacteria such as Escherichia coli, Salmonella species, Porphyromonas species and Helicobacter species. Once in the circulation (known as endotoxaemia) LPS has a marked stimulatory effect on the immune system, and LPS-mediated signalling can cause a range of pathology. In severe cases this can lead to sepsis.

Although much of the research into the physiological effects of LPS has been carried out in the setting of sepsis, LPS signalling is highly relevant to the pathophysiology of many chronic inflammatory diseases, including neurodegenerative disease, metabolic disease and cardiovascular disease, and particularly at LPS levels that sustain low-grade non-resolving inflammation. LPS should therefore be regarded in chronic diseases, even if it is present in the body at only low concentrations.

In light of these newly appreciated disease associations, we reappraise the roles of LPS signalling in the pathology of chronic diseases. We consider the structural aspects of LPS that are relevant to the immune response and how LPS, together with its effectors, influence immune signalling. We discuss the consequence of LPS-induced signalling in chronic inflammatory diseases and summarise the therapeutic knowledge generated from sepsis research that might be repositioned to manipulate LPS-driven pathways in a broad range of chronic, inflammatory diseases.

LPS: a Bacterial Wall Component
LPS is the main component of the outer membrane of most Gram-negative bacteria. LPS is composed of a lipid A hydrophobic anchor, a proximal non-repeating oligosaccharide core, and a distal chain that is typically attached to a polymer of repeating saccharide subunits called the

¹Stellenbosch University, Stellenbosch, South Africa
²Institute of Integrative Biology, University of Liverpool, Liverpool, UK
³The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark

Corresponding author:
Etheresia Pretorius, Department of Physiological Sciences, Stellenbosch University, 7602, South Africa.
E-mail: resiap@sun.ac.za

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
O-antigen that extends further from the bacterial surface (eg5,6) (Figure 1a). LPS is a potent stimulator of innate immunity in the host, with the lipid A moiety having most of the immunostimulatory activity (eg7,8). Structural variation of lipid A can alter the stimulatory capacity of LPS, which is related to patterns of acylation and phosphorylation and the presence of charged groups.8 Diversity in the polysaccharide chain also modulates the potency of LPS, and defines the serotype of the bacterium.6

Once LPS is synthesised and exported to the bacterial outer membrane, small amounts of LPS (membrane fragments) may be liberated from the bacterial surface during replication; larger amounts are set free during death or lysis. LPS is also secreted from bacteria through the production of outer membrane vesicles (OMVs).9 As LPS is an amphiphilic molecule, it can form micelles (supramolecular aggregates) above a critical concentration, which varies depending on the polysaccharide chain length.10

Typically, LPS is not considered intrinsically toxic as the endotoxic effects are primarily mediated through activation of the immune system (eg11). The sensitivity to LPS depends primarily on factors altering the susceptibility of the host rather than the actual mechanisms of LPS.

**LPS Sensing and Cell Activation**

**TLR4 Activation and the LPS Transfer Cascade**

LPS that gains access to the bloodstream, for example from the gut lumen (BOX 1), is bound by various particles. The majority of LPS (60%) circulates bound to high density lipoprotein (HDL), but also with lower affinity to other lipoproteins.12 LPS can additionally be incorporated into chylomicron particles.13,14 Circulating LPS is sensed extracellularly by Toll-like receptor 4 (TLR4) in complex with MD2 (also known as LY96), which is expressed on several cell types, particularly immune cells. LPS is transferred to the TLR4–MD2 complex at the cell surface by the accessory proteins LBP and CD14, which is a crucial step in mediating LPS recognition by the immune system15 (Figure 2). This LPS transfer cascade massively amplifies the host response by disaggregating LPS micelles (which are relatively inert and induce only
moderate immune responses) and by catalysing the formation of complexes that activate TLR4 signalling.

The TLR4–MD2 complex can be activated by structurally diverse LPS molecules. Multiple structural components of TLR4–MD2 are involved in LPS recognition, with the highly conserved lipid A portion being an important signature for recognition by the receptor complex.\textsuperscript{16} Dimerisation of the TLR4-MD2 complex on the cell surface leads to MYD88-dependent signalling and the expression of a transcription regulators such as NF\textsubscript{κ}B and activator protein 1. Subsequent internalisation of TLR4 induces MYD88-independent, TRIF-dependent signalling in endosomes and the expression of regulators such as interferon-regulatory factor 3, and eventually type 1 interferons. Ultimately this leads to the production of cytokines and chemokines such as IL-1\textbeta, IL-6, IL-8, CCL2 and TNF-\textalpha from MYD88-dependent pathways and CXCL10, CCL5, IFN-\beta and nitric oxide from MYD88-independent, TRIF-dependent pathways (see\textsuperscript{17}).

The Stimulatory Functions of LBP

LBP is an important accessory protein in the LPS transfer cascade (eg\textsuperscript{18,19} and see.\textsuperscript{15,20,21}). LBP is an acute phase protein produced by hepatocytes as well as in non-hepatic tissues such as the epithelial cells of the intestine, lungs, and gingival tissue. LBP is constitutively secreted by hepatocytes into the bloodstream and circulates at low levels, but can increase from a baseline concentration of around 1 to 15 µg/mL by more than 10- to 20-fold during the acute phase response to infections.\textsuperscript{22,23} LBP can form high-affinity complexes with LPS, with a specificity for the lipid A moiety\textsuperscript{24} (Figure 1b). LBP can extract LPS from LPS micelles\textsuperscript{25,26} and bacterial membranes,\textsuperscript{27} or LPS-rich particles like OMVs, and transfer the LPS monomers to various targets such as lipoproteins, accessory molecules and lipid domains. LBP also has an intrinsic capacity to bind to macrophage membranes in a dose-dependent manner, independently of LPS, CD14 and TLR4.\textsuperscript{10,28} Membrane-bound LBP can act as a fusion protein and enable LPS to intercalate into liposomal membrane (see\textsuperscript{10}). It has been proposed that membrane-bound LBP might have a role in cell activation. For example, LBP-mediated intercalation of LPS may induce mechanical stress on transmembrane proteins and stimulate K\textsuperscript{+} channels that are related to macrophage activation, with intercalated LPS aggregates being more activating than monomeric LPS.

\textbf{Figure 2.} The LPS transfer cascade. The transfer of LPS to TLR4–MD2 through LBP and CD14 massively amplifies the host response to extracellular LPS. (1) LBP binds longitudinally to a LPS micelle. (2) Electrostatic interactions form between LBP (bound to LPS) and CD14. (3) LPS is transferred to CD14 in multiple rounds of transfer. (4) LPS is transferred from CD14 to MD2 by interacting with the LRR13–LRR15 domain of TLR4. (5) The receptor complex of TLR4–MD2 and LPS dimerises. (6) This results in signal activation by TLR4–MD2. (7) Signalling proceeds through MYD88-dependent and MYD88-independent pathways. (8) TLR4 cooperates with various co-receptors. LPS aggregates that have been intercalated into the plasma membrane by LBP may induce mechanical stress on transmembrane proteins and ion channels and contribute to LPS signalling. Adapted from.\textsuperscript{165}
**Coreceptors and Chaperones**

TLR4 can cooperate with various co-receptors, and many other molecules are involved in LPS-induced TLR4 signalling. For example, moesin is a transmembrane protein that crosslinks with the cytoskeleton and has been found to bind CD14 to form part of the complex that activates TLR4-MD2 upon LPS stimulation. Furthermore, ion channels such as high-conductance Ca\(^{2+}\) channels and voltage-dependent K\(^{+}\) channels are activated by LPS in a dose-dependent manner and co-operate with TLR4 for cell activation. Here, voltage-dependent K\(^{+}\) channels are especially important for the NF-kB-dependent inflammatory response to LPS.

In terms of chaperones, extracellular high mobility group box 1 (HMGB1), like LBP, functions as an LPS transfer molecule and catalyses the transfer of LPS monomers from LPS aggregates to CD14 to initiate TLR4-mediated signalling. HMGB1 binds to the polysaccharide and lipid A moieties of LPS via domains located in the A and B box domains of HMGB1, respectively. HMGB1 works in concert with LPS to trigger TRIF-dependent immune responses via TLR4; downstream regulators such as receptor-interacting protein kinase 3 (RIPK3) mediate processes such as non-resolving inflammation. Furthermore, HMGB1 is a ligand of receptor for advanced glycation end products (RAGE). HMGB1 acts with LPS to promote the phosphorylation of p38 MAPK and the activation of NF-kB through RAGE and thereby enhances the proinflammatory activity of LPS. LPS actually stimulates the release of HMGB1 from cells such as hepatocytes in a process involving TLR4, caspase-11, and gasdermin D (GSDMD).

As the function of HMGB1 suggests, cell activation can occur independently of the standard LPS transfer cascade involving LBP. For example, CD14 is dispensable for cell activation at high concentrations (100-1000 ng/mL). Rough serotype LPS in particular can be recognised by the TLR4/MD-2 complex without the help of either LBP or CD14, and this direct receptor activation by rough LPS leads to efficient signalling via the MYD88-dependent pathway.

**Intracellular Sensing**

In addition to its expression on the surface of various cells, TLR4 can reside on components of the endosomal systems (eg recycling endosomes, the Golgi apparatus or endoplasmic reticulum) and detect intracellular LPS independently of cell surface TLR4. However, LPS can also trigger TLR4-independent responses upon intracellular detection (Figure 3).

LPS can access the cytoplasm by being transported into the cell via membrane-bound LBP or via HMGB1 and RAGE or by originating from the endocytosis of extracellular bacteria or their OMVs. LPS that accesses the cytoplasm is recognised and activates the non-canonical inflammasome pathway (see41).

In one delivery pathway, LBP interacts with the cell membrane independently of CD14 and TLR4-MD2 and is subsequently internalised, which offers a route for intracellular LPS trafficking. In addition to transferring LPS into the cytosol, LBP is found located adjacent to activated caspases. This presents a potential mechanism for the delivery of LPS to intracellular pattern recognition receptors and the non-canonical inflammasome.

As a second means of entry, extracellular HMGB1 mediates the translocation of LPS into the cytosol and facilitates caspase-11-dependent pyroptosis. Specifically, HMGB1 enhances LPS internalisation into endo-lysosomes via RAGE. HMGB1 then destabilises the lysosomal membrane, allowing LPS to leak into the cytosol and activate caspase-11.

In a third pathway, pathogens and OMV can be brought into the cell through endocytosis. Pathogen-containing vacuoles (or phagosomes) carry bacterial cargo into the cell and are disrupted by interferon-inducible guanylate-binding proteins (GBPs) and IRGB10. Lysis of these vacuoles releases bacteria into the cytosol. However, GBPs do not play a role in the accessibility of OMVs to the cytosol. Instead, OMVs release LPS into the cytosol from early endosomes. The exact mechanism of this release is unknown, although haemolysin can induce the rupture of OMV-containing vacuoles. GBPs also facilitate the sensing of cytoplasmic LPS (and OMVs) by functioning as cofactors for the activation of the noncanonical inflammasome.

Caspase-4 and/or caspase-5 (caspase-11 in mice) is the primary component of the noncanonical inflammasome and acts as a cytosolic receptor for LPS. This caspase-11 pathway intersects with the extracellular TLR4 pathway. For example, the TRIF pathway, downstream of TLR4, mediates the release of type I interferons that induce caspase-11 expression as well as the expression of GBPs, and is crucial for OMVs-induced caspase-11 activation. Caspase-11 also synergises with the assembled canonical NLRP3 inflammasome pathway to regulate caspase-1 processing and IL-1β and IL-18 secretion.

An outcome of caspase-11 activation is the initiation of pyroptosis. Pyroptosis plays a role in the clearance of intracellular bacteria from macrophages, which exposes pathogens to neutrophils. GSDMD is an essential effector of pyroptosis (see57,58). GSDMD is cleaved by caspase-11 and forms pores in the cell membrane that lack ion sensitivity and compromise the integrity of cellular membranes. Cleaved GSDMD also triggers NLRP3-dependent activation of caspase-1. Another upshot of this process is that NLRP3-dependent IL-1β and IL-18 could possibly exit the pyroptotic cell through the GSDMD pores.
Figure 3. Intracellular sensing of LPS and the non-canonical inflammasome. (1) Binding of PAMPs such as LPS to extracellular pattern-recognition receptors activates signal transduction cascades that induce gene expression of the components required for non-canonical inflammasome activation, a process termed “priming”. (2) Extracellular Gram-negative bacteria or their outer membrane vesicles (OMVs) can deliver LPS into the cytoplasm of host cells through endocytosis. (3) Guanylate-binding proteins (GBP) together with IRGB10 disrupt vacuoles containing pathogens, which enables LPS to be released into the cytosol. (*) LPS from OMVs are released from early endosomes, which does not involve GBP/IRGB10 mediated lysis. (4) HMGB1 promotes the internalisation of LPS into vacuoles through RAGE. (5) HMGB1 additionally permeabilises this vacuole to release LPS into the cytosol. Cytosolic LPS can be recognised by inflammatory caspsases and to provide a “triggering” signal for activation of the non-canonical inflammasome pathway. (6) The lipid A tail of LPS binds to the CARD motif of pro-caspase 4 in a direct interaction. (7) These intracellular LPS–pro-caspase 4 complexes dimerise and (8) oligomerise through the CARD motif, and proximity-induced activation leads to a catalytically active conformation of the non-canonical inflammasome. (9) The activated non-canonical inflammasome cleaves gasdermin D (GSDMD), releasing the amino-terminal fragments, (10) which form pores at the cell membrane. (11) The non-canonical inflammasome also activates the NLRP3 canonical inflammasome through an unknown mechanism, (12) and this inflammasome pathway releases IL-1β and IL-18, which is secreted through GSDMD pores. (13) LPS can additionally be delivered into cells through cell-bound LBP. (14) Intracellular transport of LPS by LBP raises the possibility of a role for LBP in the delivery of LPS to intracellular LPS receptors such as endosomal TLR4 and inflammatory caspsases.
Functions of LBP in Response to LPS

LBP does not only facilitate the transfer of LPS to the TLR4 complex to maximise LPS-induced signalling (see20,21) but has multiple functions in lipid transfer and immune regulation for the recognition and control of bacterial infections. The role of LBP in these responses is concentration dependent: at low concentrations LBP potentiates LPS-induced immune activation, whereas with the acute-phase rise in LBP concentration LBP inhibits LPS-induced cellular stimulation and promotes LPS clearance to protect the host from bacterial challenge (eg63,64). As the potency of LPS is due to the sensitivity of the host recognition system, LBP has a crucial role in modulating the effects of LPS. Thus, LBP not only induces LPS responses but also terminates them (although these functions are more complex in diseases).

The Inhibitory Functions of LBP

LBP, especially at acute phase concentrations, exhibits various inhibitory actions that attenuate the stimulatory effects of LPS23 (Figure 4). LBP can dissociate LPS from membrane-bound CD14 and inhibits the transfer of LPS from soluble CD14 and soluble MD2, thus attenuating cell signalling.64,65 LBP also promote the cellular uptake of LPS, which reduces the capacity of LPS-induced signalling through TLR4.64 However, LPS transfer or cellular uptake facilitated by LBP is likely not the most important mechanism for clearing LPS from the blood.66

The inhibitory action of LBP also depends on the ability of LBP to transfer LPS to other targets including lipoproteins such as HDL27,67, a process that neutralises LPS, particularly by interfering with the internalisation of LPS by macrophages.68 Transfer of LPS to HDL also facilitates the removal of LPS in the liver69, and LBP further mediate LPS detoxification in the liver by enhancing binding to chylomicrons in a dose-dependent manner.14

Additionally, LBP intercalated into LPS aggregates can mediate the crosslinking of several layers of lipid A, which has a neutralising effect by decreasing the accessibility of lipid A.70 This complexation increases the binding energy of the LPS in the complex as well as prevents LBP from inserting in the plasma membrane. LPS–LBP complexes in the plasma do not interact with membrane-bound LBP, which limits some of the stimulatory mechanisms of LPS.10

Furthermore, phospholipids can inhibit the binding of LPS aggregates to LBP, probably through competitive binding, and also reduce LBP-mediated transport of LPS to the cell membrane, attenuating cell activation.71 LBP additionally facilitates the binding of phosphatidylinositol and phosphatidylyserine to membrane-bound CD14 and this inhibits LPS-induced responses in monocytes by competing for binding with LPS on CD14.72

The Double-Edged Sword of LBP

The effects of LBP levels in disease are highlighted in Table 1. LBP is usually seen as a host-protective factor to manage the effects of LPS.73 It enables the immune system to respond efficiently to bacterial invasion but also exhibits a dual function by blunting these effects at high doses. However, the activity of LBP in enhancing LPS-mediated stimulation and cytokine release is also viewed as a contributor to the pathogenic state mediated by LPS. In mice, antibody-mediated depletion of LBP seemingly protects against LPS-induced toxicity,74 possibly even attenuating the onset of disease (eg diet-induced non-alcoholic fatty liver disease in mice75) and dysfunction (eg endothelial dysfunction and tissue fibrosis in a swine model of LPS-induced acute kidney injury.76) Furthermore, certain LBP gene polymorphisms are associated with an increased risk of pathology. For example, a functional variant in the LBP promoter (SNP 1683) has greater promoter inducibility, which is associated with higher median basal serum levels of LBP and a 5-fold increase in Gram-negative bacteraemia-related mortality of patients after allogeneic hematopoietic cell transplantation.77 Acute-phase levels of LBP can also potentiate rather than inhibit overwhelming inflammatory responses following LPS challenge compared with LBP knockout mice in the setting of cholestatic liver disease.78

To rehearse, the reactivity of LPS depends on the sensitivity of the host and the toxic effects of LPS are mediated by the host immune system. It could be said that LBP can contribute to damaging immune reactions by augmenting immune activation. Even so, a reduced immune response in the absence of LBP results in increased susceptibility to infection and its lethal effects.21,66,78 Nonetheless LBP is not simply a protective factor.

The Role of LPS in Chronic Disease

LPS-induced signalling — through TLR4-dependent and TLR4-independent pathways — evokes a profound inflammatory response and has a wide range of effects on cells (Figure 5). In addition to the release of various inflammatory mediators following leukocyte activation (see17), LPS also participates in other aspects of the immune response such as promoting dendritic cell maturation and migration, which links the innate immune response to adaptive immunity80,81 (the same is true for OMVs82), and promoting autophagy in macrophages through p38 MAPK dependent TLR4 signalling,83 which serves as a process that degrades sequestered pathogens. LPS also triggers the production of reactive oxygen and nitrogen species, such as through TLR4-mediated NADPH oxidase activation in macrophages,84 which leads to oxidative and nitrosative stress and damage;
reactive oxygen and nitrogen species are also linked to inflammatory signalling and toxic responses.

The excessive production of inflammatory mediators such as cytokines, chemokines and acute phase proteins, including complement component C3, C-reactive protein (CRP) and LBP, can result in overwhelming stimulation of the immune response and lead to cell damage and have lethal effects. This is epitomised in sepsis where a dysregulated host response to infection culminates in a pathological syndrome that can include disseminated intravascular coagulation and multisystem organ failure. However, there are many diseases in which LPS levels are raised in patients relative to matched controls. Here, the effects of LPS and its downstream signalling contribute to diverse pathologies.

**Neurodegenerative Disease**

LPS is implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (see). Neuroinflammation is a key pathological event in the neurodegenerative process.
Table 1. The Role of LBP in Human Disease.

| Disease                  | Relative LBP level in circulation | Effects of LBP                                                                 | References |
|--------------------------|-----------------------------------|-------------------------------------------------------------------------------|------------|
| Periodontal disease      | Higher in healthy subjects        | Local expression of LBP in gingival tissue aids the local defence to microbial challenge | 150        |
| Liver disease            | Higher in survivors               | LBP concentration is inversely associated with disease severity and outcomes in critically ill patients with cirrhosis and severe sepsis | 151        |
|                          | Higher in patients                | LBP is associated with insulin resistance and dyslipidaemia in non-alcoholic fatty liver disease | 152        |
|                          | Higher in more severe patients    | Increased LBP level correlates with the degree of steatosis in non-alcoholic fatty liver disease | 153        |
| Metabolic disorders      | Higher in overweight subjects     | Increased LBP level is associated with obesity, metabolic syndrome, and type 2 diabetes | 154        |
|                          | Increased with weight gain        | Local expression of LBP in adipose tissue is associated with inflammation- and obesity-associated adipose tissue dysfunction | 155        |
| Cardiovascular disease   | Higher with obesity and with the presence of carotid plaque | Serum LBP contributes independently to carotid intima media thickness and is a factor related to atherosclerosis | 156        |
|                          | Higher in patients with coronary artery disease | LBP level is an independent predictor of total and cardiovascular mortality in patients with coronary artery disease | 157        |
| Type 2 diabetes mellitus | Higher in patients                | Serum LBP level is associated with arterial stiffness in patients with diabetes | 158        |
| Alzheimer’s disease      | Higher in predisposed patients    | High baseline levels of LBP are associated with 30% higher odds of developing Alzheimer’s disease over a 12-year follow-up | 159        |
| Parkinson’s disease      | Lower in patients                 | Decreased LBP levels are associated with increased gut permeability and chronic invasion of LPS | 160,161    |
|                          | Lower in patient                  | High variability in LBP levels with patient and control groups limit the utility of LBP as a biomarker for Parkinson’s disease | 162        |
| Multiple sclerosis       | Higher in patients                | LBP level is positively correlated with oxidative stress in relapsing–remitting multiple sclerosis | 163        |
| Rheumatoid arthritis     | Higher in patients                | LBP level correlates to rheumatoid arthritis disease activity parameters | 164        |

Systemic inflammation is similarly an important factor and systemic exposure of animal models to LPS leads to neurodegenerative stimuli, such as β-amyloid, tau or α-synuclein, synergise to induce neurodegeneration (see 88, 90). LPS may prime microglia to neurodegenerative stimuli, and conversely neurodegenerative stimuli may prime microglia to LPS challenge. On the other hand, LPS exposure may lead to insensitive microglia with decreased activation, which reduces protective functions in the brain such as phagocytosis of protein aggregates. Either pathway leads to stressed neurons.

Indeed, LPS treatment of mice leads to cognitive impairment, which is prevented by TLR4-specific inhibitors. 91,92 LPS also activates microglia and disrupts synapses in a mechanism involving microglia-derived IL-1β and loss of synaptophysin in mice. 93 Furthermore, LPS stimulation can increase the permeability of the blood brain barrier in aged mice. 94 Although, the blood brain barrier is relatively resistant to LPS-induced disruption, LPS can cause disruption through both paracellular and transcytotic mechanisms. 95

In the context of Alzheimer’s disease, LPS associates with amyloid plaques, neurons, and oligodendrocytes in brains of patients, and causes injury, such as to myelin. 96,97 In the mouse brain, inflammation generated by systemic LPS leads to Aβ42 accumulation through increased β- and γ-secretase activities and increased expression of amyloid precursor protein, among other effects. 98 Experimentally, LPS can promote fibrillogenesis of Aβ fragments and Aβ fibrils bind directly to LPS micelles. 99 In mice, LPS-induced microglial activation also promotes hyperphosphorylation of tau through pathways involving microglial-derived IL-1 and neuronal p38 MAPK. 100

**Metabolic Disease**

Clinical studies of metabolic endotoxaemia in obese patients have demonstrated that serum levels of LPS increase with a high-fat diet. 101 High-fat meals similarly lead to increased LPS levels in non-obese 102 and diabetic 103 individuals. In mice, metabolic endotoxaemia dysregulates the inflammatory response and triggers the onset of diabetes and obesity. 104 Obesity is characterised as a state of chronic low-grade inflammation and LPS-induced signalling contributes to the proinflammatory milieu in human obesity. 105 LPS also promotes adipose dysfunction. LPS might be involved in defining the adipocyte death size, by initiating pyroptosis, and in the formation of crown-like structures in adipocytes, composed of dead adipocyte remnants and...
macrophages, as well as in promoting the transmission of macrophages to a proinflammatory phenotype (see\textsuperscript{108}). Indeed, obese patients with a higher degree of metabolic endotoxaemia experience altered expression in genes for adipose tissue function and lipogenesis as well as increased expression of inflammatory markers in this tissue.\textsuperscript{107}

**Cardiovascular Disease**

Atherosclerosis underlies the majority of cardiovascular diseases. LPS accelerates atherosclerosis in hypercholesterolemic rabbits\textsuperscript{108} as well as provokes more severe atherosclerosis in mice.\textsuperscript{109} Epidemiological studies show that subclinical endotoxaemia is a strong risk factor for the development of atherosclerosis.\textsuperscript{110} Further, TLR signalling has a prominent role in atherosclerosis (see\textsuperscript{111}), with LPS being a potential source of vascular inflammation.

Experimentally, LPS triggers inflammatory responses in human vascular endothelial cells.\textsuperscript{112} In studies of human tissue and primary cell culture, LPS induces the expression of neuraminidase-1, an enzyme involved in atherosclerosis progression, in monocytes, which is also part of a positive feedback loop that stimulates the expression of proinflammatory and proatherogenic cytokines.\textsuperscript{113} Furthermore, subclinical doses of LPS in mice reduce interleukin-1 receptor associated kinase M (IRAK-M) and induce miR-24, a microRNA precursor, in monocytes, which are important for resolving inflammation and homeostatic tolerance.\textsuperscript{114} Disruption to this system sustains the non-resolving low-grade inflammatory phenotype of monocytes, which is conducive for the aggravation of atherosclerosis.
A further way LPS experimentally contributes to atherosclerosis is by promoting lipid accumulation in human adventitial fibroblasts via TLR4 and by promoting the production of monocyte chemotactic protein (MCP)-1, an important chemokine in the initiation of atherosclerotic plaques.\textsuperscript{115} LPS additionally upregulates the expression of the Fcα/γ receptor on macrophages experimentally, which promotes the binding of oxidised-LDL/IgM complexes and the formation of foam cells.\textsuperscript{116}

**Coagulopathy**

LPS is a well-known and powerful pro-coagulant. This increases the risk for thromboembolic events, such as stroke, and can lead to more severe coagulopathy, such as disseminated intravascular coagulation. LPS upregulates the expression of tissue factor in a complement- and CD14-dependent manner,\textsuperscript{117} which is a crucial initiator of thrombin formation and consequently fibrin deposition. LPS can also bind to fibrinogen and induce misfolding.\textsuperscript{118,119} In addition to a role in coagulation, thrombin can cleave pro-IL-1α and initiates the IL-1α inflammatory cascade.\textsuperscript{120} Indeed, LPS-induced inflammatory processes promote coagulation (see\textsuperscript{4,186}). Contrariwise coagulation factors also activate inflammatory signalling pathways, largely through protease activated receptors (see\textsuperscript{121}). Inflammatory processes additionally downregulate anticoagulant mechanisms such as the anti-thrombin system, tissue factor pathway inhibitor, and the activated protein C system; an increase in plasminogen activator inhibitor decreases coagulation.\textsuperscript{122}

Activation of the noncanonical inflammasome by LPS is a further pathway that induces systemic blood clotting. Pyroptotic macrophages release tissue factor in the form of microvesicles through GSDMD pores, which initiates coagulation cascades.\textsuperscript{122} Additionally, GSDMD-mediated calcium influx and activation of scramblase enzymes cause phosphatidylserine exposure that increases tissue factor activity and further drives coagulation activation.\textsuperscript{123} Extracellular HMGB1 and its interaction with LPS for intracellular delivery promotes this process.\textsuperscript{124} The contribution of HMGB1 to LPS-induced coagulopathy is amplified by LPS-induced type I interferon signalling downstream of TLR4 that increases the extracellular release of HMGB1.\textsuperscript{124}

Furthermore, LPS, the complement system and various inflammatory mediators induce the platelet response.\textsuperscript{125} Platelet TLR4 activation is an important trigger for platelet haemostatic responses although the effect of LPS on platelet TLR4 is controversial (see\textsuperscript{126}). OMVs additionally induce platelet-platelet aggregation and degranulation as well as platelet-leukocyte binding. \textit{Ex vivo} OMVs are a more potent platelet agonist than is purified LPS.\textsuperscript{127} Platelet activation can further propagate coagulation and inflammatory signalling.\textsuperscript{128}

**Therapeutic Implications**

Research into therapeutic strategies that target bacterial LPS has mainly been carried out in the context of sepsis. These strategies aim to either neutralise or remove LPS or inhibit LPS-mediated activation of immune cells, thus reducing the dysregulated host response. However, therapies aimed at neutralising the effects of LPS by inhibiting the inflammatory response or by LPS-targeted antibodies (such as E5 and HA-1A) have been largely ineffective in treating sepsis. Nonetheless, it is worthwhile revising these therapeutic approaches when searching for potential therapies that target LPS in chronic diseases.

The monoclonal antibody HA-1A (marketed as Centoxin), which targets LPS, and recombinant human activated protein C (Drotrecogin alfa; marketed as Xigris), an anticoagulant, are notable failures of the biopharmaceutical industry.\textsuperscript{129,130} The LPS–TLR4 signalling pathway has also been considered as a target to treat sepsis,\textsuperscript{131} but the lipid A antagonist eritoran, which blocks LPS from binding to TLR4–MD2,\textsuperscript{132} and the TLR4 antagonist TAK-242\textsuperscript{133} have been ineffective in reducing sepsis mortality. Several reasons are offered to explain the failures of these approaches including the complexity of the physiological response in stressed patients; the clinically appropriate time to administer certain drugs (eg during early exposure vs. during established pathology); heterogeneity in crucially-ill patient populations; the difficulty of standardising the timing of therapeutic interventions among patients; and the presence of generic polymorphisms within the general population that are not necessarily proportionally represented in clinical trials and potentially affect trial outcome and data analysis.\textsuperscript{134} Of course, another explanation is simply that these reactions are not part of the main pathways driving sepsis.

**Targeting LPS Through Neutralising Molecules**

The development of LPS-neutralising peptides is an area of active research to treat sepsis. Protonated histidine-rich polypeptides can inhibit LPS responses by binding and neutralising LPS, although their moderate toxicity, poor solubility at physiological pH and immune activating effects limit immediate therapeutic benefit (see\textsuperscript{135}). Also, their LPS-neutralising effect is tightly coupled to the protonated state, which is largely lost at physiological pH. Other polycationic peptides such as procalcitonin\textsuperscript{136} can also neutralise LPS and reduce the expression of downstream inflammatory mediators. By contrast, arginine- and lysine-rich cationic polypeptides enhance LPS responses by shunting monomerised LPS to sites of recognition.\textsuperscript{137,138}

Nonetheless, peptide-based therapies based on LPS-binding domains are a promising approach to target and inhibit LPS. Peptides based on the iron-binding glycoprotein lactoferrin as well as defensins and fragments of saposin family proteins have been studied for their ability to neutralise LPS (see\textsuperscript{137,138}). Synthetic anti-LPS peptides\textsuperscript{139} and Pep19-2.5\textsuperscript{140}
also interact with LPS and interfere with its signalling cascade. Sushi peptides, derived from horseshoe crab, can bind LPS, compete against other binding proteins, and display detergent like properties in disrupting LPS aggregates. Recombinant or synthetic host antibacterial protein fragments with high affinity for LPS, such as bactericidal/permeability-increasing protein (BPI) and 18-kDa cationic antimicrobial protein (CAP18), have been proposed as candidate agents in adjunctive therapy for Gram-negative sepsis. However, problems in terms of the timing of treatment, possible toxicity, and probable rapid clearance from the circulation might limit the use of these fragments therapeutically.

Further to peptide-based therapies, other agents also demonstrate LPS neutralising abilities. Cationic lipids prevent LPS from evoking an immune response, possibly by trapping LPS in mixed micelles that are harder to disaggregate, thus detoxifying LPS. Intravenous administration of protein-free, phospholipid-rich emulsions can neutralise LPS but (perhaps surprisingly) these emulsions have shown no benefit in clinical trials of sepsis. Lipopolyamines such as oleoyamines can also neutralise LPS and its signalling, and are of interest due to their low toxicity, low immunogenicity, and ease of chemical synthesis. Lastly, synthetic cationic-amphiphilic polymers can detoxify LPS by binding and forming pseudoaggregates.

Other Targets to Reduce LPS and its Effects

Additional targets for treating endotoxemia might include sites of LPS release into the circulation. The gut and other focus sites (such as periodontal disease, catheters, and vascular access) are potentially reversible sources of LPS translocation into the circulation. Treatment may include the use of non-absorbable drugs that form complexes with LPS in the intestine and reduce translocation, such as sevelamer. By strengthening the intestinal epithelial barrier, nutritional management including improving dietary quality and micro-nutrient status, manipulating the gut microbiome with prebiotics and probiotics, and using certain nutritional supplements may be alternative treatment strategies to help manage circulating levels of LPS and inflammation. Indeed, natural compounds such as Zingerone from ginger attenuate LPS-induced inflammation.

Anti-inflammatory antioxidants may hold promise for neutralising the inflammatory effects of LPS, even if they do not interact with it directly. However, although using an anti-inflammatory therapy may seem a logical approach, research of sepsis has shown that extended immunosuppression (anergy) following an initial pro-inflammatory phase may be detrimental and increase susceptibility to secondary infections. Therefore, an important consideration is to restore the balance between pro-inflammatory and anti-inflammatory reactions. This offers a further example of the complex dynamics of inflammation operating in diseases such as sepsis.

Conclusions

LPS is increasingly found to be associated with chronic diseases and can cause various pathologies. Numerous mechanisms are proposed to link LPS-induced signalling and immune dysregulation to the aetio-pathogenesis of chronic diseases. The aetiologies and pathogenesis of these diseases are multifactorial with several factors contributing to their risk and progression. LPS signalling is presented in this Review as a potential common pathway operating across these conditions.

Chronic inflammatory diseases are collectively the most prevalent conditions affecting human health, representing some of the greatest burdens to society. According to WHO factsheets, more than 55 million people have dementia (60%–70% of which is Alzheimer’s disease) at an economic cost of $1.3 trillion in 2019. In 2014, 422 million people had diabetes, which accounted for 1.5 million direct deaths in 2019. Cardiovascular diseases are the leading cause of death globally at an estimated 17.9 million deaths in 2019, which represents 32% of global deaths and 38% of deaths classified as premature. Even small improvements to these statistics by regarding the role of LPS in chronic diseases could yield significant impact.

Traditionally, LPS research has been carried out in the context of sepsis, especially concerning the quest for therapeutics that target LPS. However, there exists promise for the translation of sepsis research to other pathological conditions. As an example of translation, drugs developed for sepsis treatment that improve functional outcomes (for example, by reducing morbidities, delaying the onset of organ failure, or improving outcomes on a disease-specific performance scale) but that have not been linked to reduced 28-day mortality may still show promise in other conditions where endotoxemia is less severe. Indeed, approaches that aim to reduce levels of LPS in the blood and thus mitigate its interaction with the host may lead to reduced pathology in a broad range of conditions. However, developing treatments that can lower circulating LPS levels over the long term will be challenging. Nonetheless, a starting point is to look out for and treat gut disturbances, as gut dysbiosis can be a major source for LPS to enter the blood circulation.

Overall, research in the setting of sepsis has laid a foundation for understanding LPS-induced signalling and its contribution to disease processes. Future research needs to establish the clear causal links between chronic diseases and elevated LPS. Determining the effect of therapeutics that target LPS levels or its downstream actions in chronic diseases needs to form part of these future investigations. Some success in translation has come from the failure of the antibody drug Centoxin, where experience in developing antibody therapies has informed the subsequent scientific planning and development of other antibody drugs for a number of chronic conditions (see).
Appreciating the relevance of LPS-driven pathways as contributors to pathology in a range of diseases therefore offers a novel framework for approaching these conditions that might offer new solutions to the public health burden of chronic inflammatory diseases.

**Author Contributions**

M.J.P. wrote the manuscript and prepared the figures. D.B.K. reviewed and edited the manuscript. E.P. reviewed and edited the manuscript, assisted with figure design, and is the study leader.

**Box 1 | Origins of LPS in the body**

LPS can gain entry into the body by various routes. The majority of LPS exposure arises from translocation across the gut barrier (see<sup>164</sup>). The gastrointestinal tract has many features that restrain the microbiota while maintaining a symbiotic relationship (see<sup>167</sup>). Disruption to the intestinal barrier and increased permeability of the gut lining enables pathogens (such as bacteria), antigens and toxins to enter the bloodstream, a state referred to as 'leaky gut'. This can be caused by inflammatory changes that occur in various diseases (see<sup>168</sup>), and is also closely associated with gut dysbiosis, an imbalance of gut microbiota (eg<sup>169</sup>). Dysbiosis is implicated in the degradation and control of tight junction proteins that govern permeability of intestinal epithelial cells (eg<sup>170</sup>), as well as immune dysregulation and inflammation in the intestine (see<sup>171,172</sup>). Further to this, diet, environmental stress, drug overuse, and conditions such as malnutrition or constipation may also lead to disruptions in gut barrier function and increased intestinal permeability.<sup>166,167</sup>

The bacterial product LPS has specifically been shown to translocate across the intestinal barrier and contribute to disease. LPS induces an increase in tight junction permeability through TLR4-dependent mechanisms,<sup>173–175</sup> and contributes to immune activation and inflammation that further disrupt the gut barrier. Lipid absorption by chylomicrons also function as a vehicle for LPS entry.<sup>17</sup> Direct uptake of LPS may also be mediated by M cells overlaying Peyer’s patches and by dendritic cells (see<sup>5</sup>).

LPS may further enter the circulation at other locations, such as across compromised barriers at sites of infection. For example, LPS-induced lung inflammation is linked to increased epithelial permeability in the respiratory system.<sup>176</sup> Urinary tract infections can also be a source of bacterial molecules in the blood,<sup>177</sup> as may medical equipment such as catheters and prosthetic devices.<sup>178</sup> Another major source of translocated bacteria and their products is the oral cavity (see<sup>179</sup>), with epithelial barriers being disrupted with abrasive toothbrushing, or periodontal disease and associated inflammation.<sup>180</sup> A further source of LPS is cigarette smoking (eg<sup>181</sup>).

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Novo Nordisk Foundation (NNF20CC0035580), UK Biotechnology and Biological Sciences Research Council (BB/L025752/1), Medical Research Council (MRC) of South Africa (Self-Initiated Research Program).

**Ethical Approval**

Not applicable, because this article does not contain any studies with human or animal subjects.

**Informed Consent**

Not applicable, because this article does not contain any studies with human or animal subjects.

**ORCID iD**

Martin J. Page https://orcid.org/0000-0002-2479-9182

**Trial Registration**

Not applicable, because this article does not contain any clinical trials.

**References**

1. Gargano LM, Hughes JM. Microbial origins of chronic diseases. Annu Rev Public Health 2014; 35(1): 65–82. 2013/12/25. DOI: 10.1146/annurev-publhealth-032013-182426.

2. Hand TW, Vujkovic-Cvijin I, Ridaura VK, et al. Linking the Microbiota, Chronic disease, and the immune system. Trends Endocrinol Metab 2016; 27(12): 831–843. 2016/09/14. DOI: 10.1016/j.tem.2016.08.003.

3. Kell DB, Pretorius E. On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biol (Camb) 2015; 7(11): 1339–1377. 2015/09/09. DOI: 10.1039/c5ib00158g.

4. van der Poll T, van de Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 2017; 17(7): 407–420. Review Article 2017/04/25. DOI: 10.1038/nri.2017.36.

5. Rietschel ET, Kirikae T, Schade FU, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8(2): 217–225. 1994/02/01. DOI: 10.1096/fasebj.8.2.8119492.

6. Bertani B, Ruiz N. Function and biogenesis of lipopolysaccharides. EcoSal Plus 2018; 8 (1): 1-19. DOI: 10.1128/ecosalplus.ESP-0001-2018.

7. Galanos C, Luderitz O, Rietschel ET, et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985; 148(1): 1–5. 1985/04/01. DOI: 10.1111/j.1432-1033.1985.tb08798.x.

8. Molinaro A, Holst O, Di Lorenzo F, et al. Chemistry of lipid A: at the heart of innate immunity. Chemistry 2015; 21(2): 500–519. 2014/10/30. DOI: 10.1002/chem.201403923.

9. Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 2010; 64(1): 163–184. 2010/09/10. DOI: 10.1146/annurev.micro.091208.073413.

10. Gutsmann T, Schromm AB, Brandenburg K. The physicochemistry of endotoxins in relation to bioactivity. Int J Med Microbiol 2007; 297(5): 341–352. 2007/04/25. DOI: 10.1016/j.ijmm.2007.03.004.
11. Freudenberg MA, Kalis C, Chvatchko Y, et al. Role of interferons in LPS hypersensitivity. *J Endotoxin Res* 2003; 9(5): 308–312. 2003/10/28. DOI: 10.1179/096805103225002566.

12. Levels JH, Abraham PR, van den Ende A, et al. Distribution and kinetics of lipoprotein-bound endotoxin. *Infect Immun.* 2001; 69(5): 2821–2828. 2001/04/09. DOI: 10.1128/IAI.69.5.2821-2828.2001.

13. Ghoshal S, Witta J, Zhong J, et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. *J Lipid Res.* 2009; 50(1): 90–97. 2008/09/26. DOI: 10.1194/jlr.M800156-JLR200.

14. Vreugdenhil AC, Rousseau CH, Hartung T, et al. High concentrations of toxicity-regulating proteins in bacteremia. *Infect Immun.* 2000; 68(5): 2410–2417. 2000/04/18. DOI: 10.1128/IAI.68.5.2410-2417.2000.

15. Ryu JK, Kim SJ, Rah SH, et al. Reconstruction of LPS transfer cascade reveals structural determinants within LBP, CD14, and TLR4-MD2 for efficient LPS recognition and transfer. *Immunity* 2017; 46(1): 38–350. 2016/12/18. DOI: 10.1016/j.immuni.2016.11.007.

16. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD2 complex. *Nature* 2009; 458(7242): 1191–1195. 2009/03/03. DOI: 10.1038/nature07830.

17. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. *Science* 1990; 249(4975): 1429–1431. 1990/09/21. DOI: 10.1126/science.2402637.

18. Hailman E, Vasselon T, Kelley M, et al. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. *J Immunol* 1996; 156(11): 4384–4390. 1996/06/01.

19. Ding PH, Jin LJ. The role of lipopolysaccharide-binding protein in innate immunity: a revisit and its relevance to oral/periodontal health. *J Periodontal Res* 2014; 49(1): 1–9. 2013/04/23. DOI: 10.1111/jpe.12081.

20. Schumann RR. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. *Biochem Soc Trans* 2011; 39(4): 989–993. 2011/07/27. DOI: 10.1042/BST0390989.

21. Froom AH, Dentener MA, Greve JW, et al. Lipopolysaccharide toxicity-regulating proteins in bacteremia. *J Infect Dis* 1995; 171(5): 1250–1257. 1995/05/01. DOI: 10.1093/infdis/171.5.1250.

22. Zweigner J, Gramm HJ, Singer OC, et al. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. *Blood* 2001; 98(13): 3800–3808. 2001/12/12. DOI: 10.1182/blood.v98.13.3800.

23. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. *J Biol Chem* 1989; 264(18): 10867–10871. 1989/06/25. DOI: 10.1016/S0021-9258(18)81700-8.

24. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. *J Biol Chem* 1996; 271(8): 4100–4105. 1996/02/23. DOI: 10.1074/jbc.271.8.4100.

25. Wurfel MM, Wright SD. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. *J Immunol* 1997; 158(8): 3925–3934. 1997/04/15.

26. Vesy CJ, Kitchens RL, Wollbauer G, et al. Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from gram-negative bacterial membranes. *Infect Immun.* 2000; 68(5): 2410–2417. 2000/04/18. DOI: 10.1128/IAI.68.5.2410-2417.2000.

27. Kopp F, Kupsch S, Chromm AB. Lipopolysaccharide-binding protein is bound and internalized by host cells and colocalizes with LPS in the cytoplasm: implications for a role of LBP in intracellular LPS-signaling. *Biochim Biophys Acta* 2016; 1863(4): 660–672. 2016/01/26. DOI: 10.1016/j.bbcanr.2016.01.015.

28. Youn JH, Kim ES, Oh YJ, et al. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated NF-κB signaling in macrophages. *J Periodontal Res* 2010; 45(5): 589–601. 2010/06/16. DOI: 10.1111/j.1600-0765.2010.01271.x.

29. Yon Oh YJ, Kim ES, et al. Lipopolysaccharide-binding protein release lipopolysaccharides from gram-negative bacteria. *J Biol Chem* 1996; 271(8): 4100–4105. 1996/02/23. DOI: 10.1074/jbc.271.8.4100.

30. Papavlassopoulos M, Stamme C, Thon L, et al. Maxik blockade selectively inhibits the lipopolysaccharide-induced ICAM-1/NF-κB signaling pathway in macrophages. *J Immunol* 2006; 177(6): 4086–4093. 2006/03/10. DOI: 10.4049/jimmunol.177.6.4086.

31. Youn JH, Kwak MS, Wu J, et al. Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model. *Eur J Immunol* 2011; 41(9): 2753–2762. 2011/06/11. DOI: 10.1002/eji.201141391.

32. Meng R, Gu L, Lu Y, et al. High mobility group box 1 enables bacterial lipids to trigger receptor-interacting protein kinase 3 (RIPK3)-mediated necroptosis and apoptosis in mice. *J Biol Chem* 2019; 294(22): 8872–8884. 2019/04/20. DOI: 10.1074/jbc.RA118.007040.

33. Qiu YH, Dai SM, Tang GS, et al. HMGB1 Enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. *J Immunol* 2009; 183(10): 6244–6250. 2009/11/06. DOI: 10.4049/jimmunol.0900390.

34. Deng M, Tang Y, Li W, et al. The endotoxin delivery protein HMGB1 mediates caspase-1-dependent lethality in sepsis. *Immunity* 2018; 49(4): 740–753, e1-e7. 2018/10/14. DOI: 10.1016/j.immuni.2018.08.016.

35. Li W, Deng M, Loughran PA, et al. LPS Induces active HMGB1 release From hepatocytes Into exosomes through the coordinated activities of TLR4 and caspase-11/GSDMD signaling. *Front Immunol* 2020; 11: 229. 2020/04/25. DOI: 10.3389/fimmu.2020.00229.

36. Borzecka K, Plociennikowska A, Bjorkelund H, et al. CD4 Mediates binding of high doses of LPS but is dispensable for TNF-alpha production. *Mediators Inflamm.* 2013; 2013: 753, e1-e7. 2013/10/06. DOI: 10.1155/2013/753.

37. Huber M, Kalis C, Keck S, et al. R-form LPS, the master key to the activation of TLR4/MD-2-positive cells, *Eur J Immunol* 2006; 36(3): 701–711. 2006/03/01. DOI: 10.1002/eji.200535593.
39. Jiang Z, Georgel P, Du X, et al. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005; 6(6): 565–570. 2005/05/17. DOI: 10.1038/ni1207.

40. Shibata T, Motoi Y, Tanimura N, et al. Intracellular TLR4/MD-2 in macrophages senses gram-negative bacteria and induces a unique set of LPS-dependent genes. Int Immunol 2011; 23(8): 503–510. 2011/06/30. DOI: 10.1093/antimm/dxr044.

41. Rathinam VAK, Zhao Y, Shao F. Innate immunity to intracellular LPS. Nat Immunol 2019; 20(5): 527–533. 2019/04/10. DOI: 10.1038/s41590-019-0368-3.

42. Santos JC, Dick MS, Lagrange B, et al. LPS Targets host guanylate-binding proteins for cytosolic bacteria. Cell 2016; 165(5): 1106–1119. 2016/05/10. DOI: 10.1016/j.cell.2016.04.015.

43. Meunier E, Dick MS, Dreier RF, et al. Caspase-11 activation by bacterial outer membrane vesicles. Cell 2017; 169(1): e1188–e1190. 2017/10/05. DOI: 10.1016/j.cell.2017.08.025.

44. Vanaja SK, Russo AJ, Behl B, et al. TRIF Licenses caspase-11-dependent pyroptosis in response to gram-negative bacteria. Cell 2012; 150(3): 606–619. 2012/07/24. DOI: 10.1016/j.cell.2012.07.007.

45. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 2017; 42(4): 245–254. 2016/12/10. DOI: 10.1016/j.tibs.2016.10.004.

46. Hamann L, Alexander C, Stamme C, et al. Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit LPS and enhance LPS-induced activation of mononuclear cells. Infect Immun 2001; 69(1): 6942–6950. 2001/10/13. DOI: 10.1128/IAI.69.11.6942-6950.2001.

47. He WT, Wan H, Hu L, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res 2015; 25(12): 1285–1298. 2015/11/28. DOI: 10.1038/cr.2015.139.

48. Rathinam VA, Estevez A, Gupta A, et al. Gsdmd p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc Natl Acad Sci U S A 2016; 113(28): 7758–7763. 2016/06/25. DOI: 10.1073/pnas.1607769113.

49. Gutsmann T, Muller M, Carroll SF, et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69(11): 6942–6950. 2001/10/13. DOI: 10.1128/IAI.69.11.6942-6950.2001.

50. Hamann L, Alexander C, Stamme C, et al. Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms. Infect Immun. 2005; 73(1): 193–200. 2004/12/25. DOI: 10.1128/IAI.73.1.193-200.2005.

51. Thompson PA, Tobias PS, Viriyakosol S, et al. Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003; 278(31): 28367–28371. 2003/05/20. DOI: 10.1074/jbc.M302921200.

52. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997; 389(6665): 742–745. 1997/10/24 21:29. DOI: 10.1038/39622.

53. Wurfel MM, Kunitake ST, Lichenstein H, et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180(3): 1025–1035. 1994/09/01. DOI: 10.1084/jem.180.3.1025.
68. Freudenberg MA, Galanos C. Metabolism of LPS in vivo. In: Morrison DC, Ryan JL (eds) Bacterial Endotoxic Lipopolysaccharides, Vol 2: Immunopharmacology and Pathophysiology. 275–294. Boca Raton: CRC Press, 1992.

69. Yao Z, Mates JM, Cheplowitz AM, et al. Blood-Borne lipopolysaccharide is rapidly eliminated by liver sinusoidal endothelial cells via high-density lipoprotein. J Immunol 2016; 197(6): 2390–2399. 2016/08/19. DOI: 10.4049/jimmunol.1600702.

70. Roes S, Munn F, Seydel U, et al. Localization of the lipopolysaccharide-binding protein in phospholipid membranes by atomic force microscopy. J Biol Chem 2006; 281(5): 2757–2763. 2005/11/24. DOI: 10.1074/jbc.M507634200.

71. Mueller M, Brandenburg K, Dedrick R, et al. Phospholipids inhibit lipopolysaccharide (LPS)-induced cell activation: a role for LPS-binding protein. J Immunol 2005; 174(2): 1091–1096. 2005/01/07. DOI: 10.4049/jimmunol.174.2.1091.

72. Wang PY, Kitchens RL, Munford RS. Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide. J Biol Chem 1998; 273(38): 24309–24313. 1998/09/12. DOI: 10.1074/jbc.273.38.24309.

73. Lamping N, Dettmer R, Schroder NW, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest. 1998; 101(10): 2065–2071. 1998/05/29. DOI: 10.1172/JCI2338.

74. Gallay P, Heumann D, Le Roy D, et al. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxin-mediated shock. Proc Natl Acad Sci USA 1993; 90(21): 9935–9938. 1993/11/10. DOI: 10.1073/pnas.90.21.9935.

75. Jin CJ, Engstler AJ, Ziegenhardt D, et al. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease in mice. J Gastroenterol Hepatol 2017; 32(3): 708–715. 2016/07/13. DOI: 10.1111/jgh.13488.

76. Castellano G, Stasi A, Intini A, et al. Endothelial dysfunction and renal fibrosis in endotoxemia-induced oliguric kidney injury: possible role of LPS-binding protein. Crit Care 2014; 18(5): 520. 2014/09/28. DOI: 10.1186/s13054-014-0520-2.

77. Chien JW, Boehm MJ, Hansen JA, et al. Lipopolysaccharide binding protein promoter variants influence the risk for gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008; 111(4): 2462–2469. 2007/12/07. DOI: 10.1182/blood-2007-09-101709.

78. Minter RM, Bi X, Ben-Josef G, et al. LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction. Am J Physiol Gastrointest Liver Physiol 2009; 296(1): G45–G54. 2008/10/25. DOI: 10.1152/ajpgi.00041.2008.

79. Branger J, Florquin S, Knapp S, et al. LPS-binding protein-deficient mice have an impaired defense against gram-negative but not gram-positive pneumonia. Int Immunol 2004; 16(11): 1605–1611. 2004/09/29. DOI: 10.1093/intimm/dxh161.

80. Grobner S, Lukowski R, Autenrieth IB, et al. Lipopolysaccharide induces cell volume increase and migration of dendritic cells. Microbiol Immunol 2014; 58(1): 61–67. 2013/11/19. DOI: 10.1111/1348-0421.12116.

81. Granucci F, Ferrero E, Foti M, et al. Early events in dendritic cell maturation induced by LPS. Microbes Infect 1999; 1(3): 1079–1084. 1999/12/03. DOI: 10.1016/s1286-4579(99)00209-9.
oxidative stress, neuroinflammation, and elements of the neurovascular unit. *J Neuroinflammation* 2015; 12(1): 223. 2015/11/27. DOI: 10.1186/s12974-015-0434-1.

96. Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. *Front Aging Neurosci* 2018; 10: 42. 2018/03/10. DOI: 10.3389/fnagi.2018.00042.

97. Zhan X, Stamova B, Jin LW, et al. Gram-negative bacterial molecules associate with Alzheimer disease pathology. *Neurology* 2016; 87(22): 2324–2332. 2016/10/28. DOI: 10.1212/WNL.000000000003391.

98. Lee JW, Lee YK, Yek DY, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. *J Neuroinflammation* 2008; 5(1): 37. 2008/09/02. DOI: 10.1186/1742-2094-5-37.

99. Asti A, Gioglio L. Can a bacterial endotoxin be a key factor in the kinetics of amyloid fibril formation? *J Alzheimer’s Dis* 2014; 39(1): 169–179. 2013/10/24. DOI: 10.3233/JAD-131394.

100. Bhaskar K, Konerth M, Kokiko-Cochran ON, et al. Metabolic endotoxemia and pyroptosis during obesity. *Diabetes Care* 2012; 35(3): 973–978. 2012/03/08. DOI: 10.1194/jdr.P200909.

101. Clemente-Postigo M, Queipo-Ortuno MI, Murri M, et al. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. *J Lipid Res.* 2012; 53(3): 973–978. 2012/03/08. DOI: 10.1194/jlr.P020909.

102. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces low-grade endotoxaemia: evidence of a novel mechanism of postprandial inflammation. *Am J Clin Nutr* 2007; 86(5): 1286–1292. 2007/11/10. DOI: 10.1093/ajcn/86.5.1286.

103. Harte AL, Varma MC, Tripathi G, et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. *Diabetes Care* 2012; 35(2): 375–382. 2012/01/03. DOI: 10.2337/dc11-1593.

104. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 2007; 56(7): 1761–1772. 2007/04/26. DOI: 10.2337/db06-1491.

105. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. *Am J Physiol Endocrinol Metab* 2007; 292(3): E740–E747. 2006/11/09. DOI: 10.1152/ajpendo.00302.2006.

106. Hersoug LG, Moller P, Loft S. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity. *Nutr Res Rev* 2018; 31(2): 153–163. 2018/01/25. DOI: 10.1016/j.nutrresrev.2017000269.

107. Clemente-Postigo M, Oliva-Olivera W, Coin-Araguez L, et al. Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. *Am J Physiol Endocrinol Metab* 2019; 316(2): E319–E332. 2018/11/14. DOI: 10.1152/ajpendo.00277.2018.

108. Lehr HA, Sagban TA, Ilhing C, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. *Circulation* 2001; 104(8): 914–920. 2001/08/22. DOI: 10.1161/hc3401.093153.

109. Ostos MA, Recalde D, Zakim MM, et al. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. *FEBS Lett* 2002; 519(1-3): 23–29. 2002/05/23. DOI: 10.1016/s0014-5793(02)02692-3.

110. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxia with carotid atherosclerosis and cardiovascular disease: prospective results from the bruneck study. *J Am Coll Cardiol* 1999; 34(7): 1975–1981. 1999/12/10. DOI: 10.1016/s0735-1097(99)00448-9.

111. Falck-Hansen S, Kassiteridi C, Monaco C. Toll-like receptors in atherosclerosis. *Int J Mol Sci.* 2013; 14(7): 14008–14023. 2013/07/25. DOI: 10.3390/ijms140714008.

112. Triantaflou M, Gamper FG, Lepper PM, et al. Lipopolysaccharides from atherosclerosis-associated bacteria antagonize TLR4, induction of TLR2/1/CD36 complexes in lipid rafts and trigger TLR2-induced inflammatory responses in human vascular endothelial cells. *Cell Microbiol* 2007; 9(8): 2030–2039 2007/04/11. DOI: 10.1111/j.1462-5822.2007.00935.x.

113. Sieve I, Riecke-Hoch M, Kasten M, et al. A positive feedback loop between IL-1beta, LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. *Vascular Pharmacol* 2018; 103–105: 16–28 2018/01/27. DOI: 10.1016/j.vph.2018.01.005.

114. Geng S, Chen K, Yuan R, et al. The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis. *Nat Commun* 2016; 7(1): 13436 2016/11/09. DOI: 10.1038/ncomms13436.

115. Wang J, Si Y, Wu C, et al. Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-kappaB pathway. *Lipids Health Dis* 2016; 11(1): 139 2012/10/18. DOI: 10.1186/1476-511X-11-139.

116. Feng X, Zhang Y, Xu R, et al. Lipopolysaccharide up-regulates the expression of fcα/μ receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. *Atherosclerosis* 2010; 208(2): 396–405 2009/08/18. DOI: 10.1016/j.atherosclerosis.2009.07.035.

117. Landsem A, Fure H, Christiansen D, et al. The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. *Clin Exp Immunol* 2015; 182(1): 81–89 2015/08/05. DOI: 10.1111/cei.12663.

118. Pretorius E, Mbotwe S, Bester J, et al. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. *J R Soc Interface* 2016; 13(122): 20160539 2016/09/09. DOI: 10.1098/rsif.2016.0539.

119. Pretorius E, Page MJ, Hendricks L, et al. Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel amytracker stains. *J R Soc Interface* 2018; 15(139): 20170941 2018/02/16. DOI: 10.1098/rsif.2017.0941.

120. Burzynski LC, Humphry M, Pyrillou K, et al. The coagulation and immune systems Are directly linked through the activation of interleukin-1alpha by thrombin. *Immunity* 2019; 50(6): 1401–1411 e1-e4. 2019/05/12. DOI: 10.1016/j.immuni.2019.04.003.
153. Kitabatake H, Tanaka N, Fujimori N, et al. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. *World J Gastroenterol* 2017; 23(4): 712–722. 2017/02/22. DOI: 10.3748/wjg.v23.i4.712.

154. Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. *Diabetes Care* 2010; 33(9): 1925–1932. 2010/06/10. DOI: 10.2337/dc10-0340.

155. Moreno-Navarrete JM, Escote X, Ortega F, et al. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. *Diabetologia* 2013; 56(11): 2524–2537. 2013/08/22. DOI: 10.1007/s00125-013-3015-9.

156. Serrano M, Moreno-Navarrete JM, Puig J, et al. Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. *Atherosclerosis* 2013; 230(2): 223–227. 2013/10/01. DOI: 10.1016/j.atherosclerosis.2013.07.004.

157. Lepper PM, Kleber ME, Grammer TB, et al. Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease—results from the Ludwigshafen risk and cardiovascular health study (LURIC). *Atherosclerosis* 2021; 219(1): 291–297. 2021/07/05. DOI: 10.1016/j.atherosclerosis.2021.06.001.

158. Sakura T, Moritaoka T, Shioi A, et al. Lipopolysaccharide-binding protein is associated with arterial stiffness in patients with type 2 diabetes: a cross-sectional study. *Cardiovasc Diabetol* 2017; 16(1): 62. 2017/05/11. DOI: 10.1186/s12933-017-0545-3.

159. Andre P, Samieri C, Buissin C, et al. Lipopolysaccharide-Binding protein, soluble CD14, and the long-term risk of Alzheimer disease. *J Am J Cardiol* 2010; 33(9): 1925–1932. 2011/07/05. DOI: 10.1016/j.atherosclerosis.2011.06.001.

160. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. *Exp Mol Med* 2018; 50(8): 1–9. 2018/08/18. DOI: 10.1038/s12276-018-0126-x.

161. Fukui H. Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation? *Inflamm Intest Dis* 2016; 1(3): 135–145. 2016/10/01. DOI: 10.1159/000447252.

162. Yu LC. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. *J Biomed Sci* 2018; 25(1): 79. 2018/11/11. DOI: 10.1186/s12929-018-0483-8.

163. Pruteanu M, Shanahan F. Digestion of epithelial tight junction proteins by the commensal Clostridium perfringens. *Am J Physiol Gastrointest Liver Physiol* 2013; 305(10): G740–G748. 2013/09/28. DOI: 10.1152/ajpgi.00316.2012.

164. Levy M, Kolodziejczyk AA, Thaiss CA, et al. Dysbiosis and the immune system. *Nat Rev Immunol* 2017; 17(4): 219–232. 2017/03/07. DOI: 10.1038/nri.2017.7.

165. Tilg H, Zmora N, Adolph TE, et al. The intestinal microbiota fuelling metabolic inflammation. *Nat Rev Immunol* 2020; 20(1): 40–54. 2019/08/08. DOI: 10.1038/s41577-019-0198-4.

166. Guo S, Al-Sadi R, Said HM, et al. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. *Am J Pathol.* 2013; 182(2): 375–387. 2012/12/04. DOI: 10.1016/j.ajpath.2012.10.014.

167. Guo S, Nighot M, Al-Sadi R, et al. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. *J Immunol* 2015; 195(10): 4999–5010. 2015/10/16. DOI: 10.4049/jimmunol.1402598.

168. Nighot M, Al-Sadi R, Guo S, et al. Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4/myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression. *Am J Pathol.* 2017; 187(2): 2698–2710. 2017/11/22. DOI: 10.1016/j.ajpath.2017.08.005.

169. Eutamene H, Theodorou V, Schmidlin F, et al. LPS-induced lung inflammation is linked to increased epithelial permeability: role of MLCK. *Eur Respir J* 2005; 25(5): 789–796. 2005/05/03. DOI: 10.1183/09031936.05.0064704.

170. Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 2015; 13(5): 269–284. 2015/04/09. DOI: 10.1038/nrmicro3432.

171. Dwyer A. Surface-treated catheters—a review. *Semin Dial* 2008; 21(6): 542–546. 2008/11/13. DOI: 10.1111/j.1525-139X.2008.00499.x.

172. Han YW, Wang X. Mobile microbiome: oral bacteria in extraoral infections and inflammation. *J Dent Res* 2013; 92(6): 485–491. 2013/04/30. DOI: 10.1177/0022034513487559.

173. Tomas I, Diz P, Tobias A, et al. Periodontal health status and bacteremia from daily oral activities: systematic review/meta-analysis. *J Clin Periodontol* 2012; 39(3): 213–228. 2011/11/19. DOI: 10.1111/j.1600-051X.2011.01784.x.

174. Meyer PWA, Ally M, Tikly M, et al. Tobacco-Derived lipopolysaccharide, Not microbial translocation, as a potential contributor to the pathogenesis of rheumatoid arthritis. *Mediators Inflamm* 2019; 2019: 4693870. 2019/11/30. DOI: 10.1155/2019/4693870.